Technology Transfer Sponsored by
A recent clinical study conducted by the University of Miami investigated whether the drug Lumigan (bimatoprost), a product marketed by Allergan and used to treat eye conditions such as glaucoma and ocular hypertension, increased eyelash length. Subjects were recruited from the Bascom Palmer Eye Institute and participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively.
The suspension was applied to the eyelashes every evening on the designated eye for six weeks. Lash length was measured with a caliper at enrollment, at weekly intervals during the study, and at 1 and 3 months after study completion. Visual acuity, ocular symptoms, intraocular pressure and photographs were documented at these same intervals.
Results indicated that the average eyelash growth in the bimatoprost group was 2.01 mm, compared with the control average of 1.13mm, which was a statistically significant difference (p=0.009). The average intraocular pressure decreased equally in both groups (2.14 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Researchers concluded the data showed an increase in eyelash length with the use of bimatoprost in gel suspension, suggesting eyelash-lengthening properties. For more information, visit www.clinicaltrials.gov.